IngentaConnect Angiotensin II receptor blockers in the prevention of atrial fibr...

Authors: Barra, Silvia; Silvestri, Nunzia; Vitagliano, Giancarlo; Madrid, Alfredo; Gaeta, Giovanni

Source: Expert Opinion on Pharmacotherapy, Volume 10, Number 9, June 2009 , pp. 1395-1411(17)

Purchase options

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$99.00 plus tax Refund Policy

Abstract:

Atrial fibrillation (AF) is the most common sustained arrhythmia. While antiarrhythmic agents and electrical cardioversion are highly effective in restoring sinus rhythm, the results obtained in prevention of recurrences are disappointing. Recently, angiotensin II has been recognized as a key factor in atrial structural and electrical remodeling associated with AF. So there are several potential mechanisms by which inhibition of the renin-angiotensin-aldosterone system may reduce AF. In this review, we report the results of studies evaluating the effect of angiotensin II receptor blockers (ARBs) in various clinical settings (i.e., lone AF, hypertension, high-risk patients, congestive heart failure, secondary prevention). However, many of these studies are small and retrospective and have a limited follow-up; moreover, since AF is related to several causes, chiefly heart diseases, patients with different characteristics have often been enrolled. Thus, it is not surprising that the results obtained are frequently conflicting. With these limitations and considering only the results of larger studies with longer follow-up, ARBs are effective in preventing AF in patients with congestive heart failure or hypertension with left ventricular hypertrophy or coronary artery/cerebrovascular disease. In any case, the use of ARBs is not recommended at present in clinical practice to prevent AF.

Keywords: angiotensin II receptor blockers; atrial fibrillation; clinical trials; prevention

Document Type: Research article

DOI: 10.1517/14656560902973736

Angiotensin II receptor blockers in the prevention of atrial fibrillation